Does MOGAMULIZUMAB Cause Malignant neoplasm progression? 10 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Malignant neoplasm progression have been filed in association with MOGAMULIZUMAB (POTELIGEO). This represents 2.3% of all adverse event reports for MOGAMULIZUMAB.
10
Reports of Malignant neoplasm progression with MOGAMULIZUMAB
2.3%
of all MOGAMULIZUMAB reports
5
Deaths
2
Hospitalizations
How Dangerous Is Malignant neoplasm progression From MOGAMULIZUMAB?
Of the 10 reports, 5 (50.0%) resulted in death, 2 (20.0%) required hospitalization, and 1 (10.0%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for MOGAMULIZUMAB. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does MOGAMULIZUMAB Cause?
Rash (59)
Disease progression (46)
Infusion related reaction (42)
Pyrexia (35)
Febrile neutropenia (29)
Erythema (28)
Pruritus (26)
Drug ineffective (24)
Constipation (22)
Death (21)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which MOGAMULIZUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
MOGAMULIZUMAB vs MOGAMULIZUMAB-KPKC
MOGAMULIZUMAB vs MOLNUPIRAVIR
MOGAMULIZUMAB vs MOLSIDOMINE
MOGAMULIZUMAB vs MOMELOTINIB
MOGAMULIZUMAB vs MOMETASONE